Positive Phase II Results Boost Astex Shares
By Catherine Shaffer
Wednesday, August 28, 2013
Shares of Astex Pharmaceuticals Inc. surged 24 percent Wednesday on top-line results from the company’s Phase II trial of cancer candidate SGI-110 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.